Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals
(Reuters) -German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment Eylea, giving it a potential edge over Roche's rival treatment Vabysmo.
Bayer said in a statement the European Medicines Agency recommended that eye drug Eylea, at a high dose of 8 mg, can be injected at intervals of up to six months to treat wet age-related macular degeneration and diabetic macular oedema.
Bayer shares were up 2.5% at 0717 GMT, surpassing a gain of 0.7% in the Stoxx Europe 600 Health Care index.
Eylea, an injection against the leading causes of blindness among the elderly, is currently approved in the EU for treatment intervals of up to five months. Bayer has developed it jointly with Regeneron.
Vabysmo, a major driver of revenue growth for Switzerland's Roche, is cleared to be given at intervals of up to four months.
The EU commission has the final say on drug approval but it typically follows the medicines agency's opinions. Bayer said that decision is expected within the next few weeks.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
BioNTech buys mRNA, courtroom rival CureVac in all-stock deal
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. COVID vaccine maker BioNTech is buying rival CureVac, announcing Thursday an all-stock deal weeks before the two companies were due to face off in a German court over potentially billions of dollars worth of royalties related to intellectual property on messenger RNA drugs. Per deal terms, each CureVac share will be exchanged for about $5.46 worth of BioNTech's U.S.-listed shares, valuing the company at $1.25 billion. Upon the deal's close, CureVac shareholders will own between 4% and 6% of BioNTech. In the early days of the COVID-19 pandemic, BioNTech and CureVac were among the companies racing to develop the first coronavirus vaccines. BioNTech, however, partnered with Pfizer and won approval of the first COVID-19 shot, while CureVac's program never made it to market. The two companies have since been embroiled in patent litigation. CureVac was a leading candidate to develop the first COVID-19 vaccine, launching rumors, later denied, that the U.S. government might even buy the company or its research. But while BioNTech and fellow mRNA drugmaker Moderna succeeded in making vaccines that saved millions of lives and earned billions of dollars in revenue, CureVac fell short. Its initial project wasn't effective enough at preventing sickness, prompting it to scrap development. A year later, CureVac sued BioNTech, claiming it infringed four patents. CureVac has since changed course, selling off most rights to influenza and COVID-19 vaccines to partner GSK and focusing on cancer instead. But its legal spat with BioNTech has lingered. The European Patent Office had upheld two CureVac patents, and a trial in a Dusseldorf regional court was set on July 1 to determine if BioNTech had infringed on them. A separate trial in the U.S. was scheduled to begin Sept. 8 in Virginia. Some Wall Street analysts, as a result, speculated that BioNTech's primary purpose is buying CureVac is to sidestep the risk of a loss in court. A single-digit percentage royalty awarded to CureVac could've cost BioNTech as much as $3 billion, Evercore ISI analyst Umer Raffat wrote in a note to clients. 'It seems to us that [BioNTech] assessed the cost of a cash settlement as substantially greater than the cost of buying [CureVac] outright,' Raffat wrote. The deal could also help BioNTech further its oncology ambitions. Like CureVac, BioNTech has made cancer research a top priority. It's invested in a variety of programs, from cell therapies to mRNA vaccines and a coveted type of bispecific antibody. Some are in advanced testing. CureVac's cancer vaccines are in earlier phases of development. A brain cancer shot has delivered early clinical data, while a lung cancer immunotherapy was cleared in April for human testing. The deal should help CureVac because of 'the early stage of the oncology pipeline and the need for a development partner to effectively compete in personalized cancer vaccines – which [BioNTech] is well positioned to execute,' wrote Leerink Partners analyst Mani Foroohar. Raffat, of Evercore ISI, however, wrote that the deal ascribes 'very little value' to CureVac's pipeline. Recommended Reading Recursion to acquire two Canadian drug discovery startups Sign in to access your portfolio
Yahoo
10 hours ago
- Yahoo
Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Report: Multispecific Antibodies Market to Surpass USD 50 Billion by 2030
Explore the booming Global Multispecific Antibodies Market set to surpass USD 50 billion by 2030. Key highlights include sales insights, approved drugs, and clinical trials from over 700 antibodies. Significant contributors like Roche and rising players ensure ongoing innovation in this dynamic biopharma sector. Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Global Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Insight 2030" report has been added to Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Insight 2030 Report Highlights: Global Multispecific Antibodies Market Opportunity By 2030: > USD 50 Billion Global Multispecific Antibodies Market Sales In 2024: > USD 12 Billion Number Of Approved Multispecific Antibodies: 18 Global & Regional Trends Insight Approved Antibodies Global, Regional, Annual & Quarterly Sales Insight Approved Antibodies Dosage & Pricing Insight Comprehensive Insight On All Antibodies In Clinical Trials By Company, Country, Indication & Phase Number Of Multispecific Antibodies: In Clinical Trials: > 700 Multispecific antibodies market globally has been one of the most energetic and fast growing sectors in the biopharmaceutical business as a result of therapeutic breakthroughs and growing acceptance of their ability to treat complicated pathologies by targeting multiple pathways simultaneously. As of May 2025, 18 multispecific antibodies have gained regulatory approval globally, all of which are bispecific constructs, a monumental milestone in the history of targeted therapeutics. This expanding portfolio boasts trailblazing drugs like Blincyto, the first bispecific antibody to gain approval, and Hemlibra, which was the first bispecific antibody to be approved for a non-cancer indication. The latest entrant to this therapeutic pipeline is Regeneron's Lynozyfic, which received marketing approval in April 2025 for the treatment of multiple myeloma, with evidence of ongoing momentum in the segment. The range of approved multispecific antibodies mirrors the flexibility of this therapeutic modality across various disease indications and patient bases. Rybrevant is another key breakthrough as the first bispecific antibody for a solid tumor, whereas China based Akeso's Cadonilimab is especially noteworthy for being solely approved bispecific antibody intended to target two immune checkpoints at once and becoming the first China developed bispecific antibody to gain regulatory approval. This regional variation in development emphasizes the world nature of innovation in this sector, with input from both mature pharmaceutical markets and developing biotechnology centers. The regulatory environment is still changing at a rapid pace, with further approvals expected in the near future. The FDA is also evaluating marketing applications for Odronextamab and Linvoseltamab, both of which have already received approval in the EU for follicular lymphoma and diffuse large B-cell lymphoma, and multiple myeloma, respectively. Such transatlantic regulatory advancements reflect the growing acceptability and trust in multispecific antibody technologies by global regulatory bodies. Market performance has been extremely strong, with global multispecific antibodies market sales in 2024 amounting to over US$ 12.6 Billion, followed by first quarter 2025 sales of over US$ 3.46 Billion. The US is the largest contributor to these sales, highlighting the maturity and acceptance of the market in this prime geography. Roche's mature products, Hemlibra and Vabysmo, lead the market share, with over half of total sales, emphasizing the value of first mover benefit and effective market entry strategies in this competitive market. The pipeline for development is an even more daunting picture, with more than 900 multispecific antibodies already in various stages of development. Oncology is leading this pipeline, both due to the traditional priority of multispecific antibody development and due to the large unmet medical needs in cancer treatment. However, pipeline diversity is not confined to oncology alone with promising candidates being identified in autoimmune and inflammatory diseases and neurological disorders as well, indicating an expanding therapeutic horizon that has the potential to dramatically expand market opportunities. Major industry players behind this innovation are well established pharma giants like Amgen, AstraZeneca, Genentech, and Regeneron, as well as new biotech firms like ABL Bio, Harbour BioMed, Innovent Biologics, Merus, and Zymeworks. This combination of well established and new players provides a vibrant competitive landscape that ensures ongoing innovation and technological progress. Strategic alliances continue to influence the development of the market, such as in the April 2025 alliance of Boehringer Ingelheim and Cue Biopharma for the development of CUE-501, a bispecific candidate that attacks pathogenic B cells via virus-specific memory T cells. The alliance, involving a US$ 12 Million upfront payment and possible milestone payments of up to US$ 345 Million, illustrates the high financial investment that companies are undertaking to drive multispecific antibody technologies, specifically in autoimmune indications where existing treatments are still inadequate. Regulatory encouragement of innovation continues to be robust, with the FDA's April 2025 fast track designation of ISB 2001, an Ichnos Glenmark Innovation investigational trispecific T-cell engager for relapsed or refractory multiple myeloma, reflecting ongoing regulatory enthusiasm for moving multispecific antibody technologies forward that treat important unmet medical needs. As a result of these ongoing innovations, the global multispecific antibody market is expected to grow rapidly and is on track to become one of the most important segments within the pharmaceutical industry. Key Topics Covered: 1. Introduction to Next Generation Multispecific Antibodies 2. Next Generation Multispecific Antibody Current Clinical Development & Future Commercialization Outlook2.1 Current Market Overview2.2 Future Commercialization Opportunity2.3 Collaborations, License Agreements, Investments & Acquisitions2.4 Next Generation Multispecific Antibody Proprietary Technologies By Company 3. Next Generation Multispecific Antibody Clinical Trends by Indication3.1 Cancer3.2 Hematological Disorders3.3 Microbial Infections3.4 Autoimmune & Inflammatory Disorders3.5 Ocular Diseases 4. Next Generation Multispecific Antibody Clinical Development & Market Trends by Region4.1 US4.2 EU4.3 China4.4 UK4.5 Japan4.6 Australia4.7 South Korea4.8 Canada 5. Approved Multispecific Antibodies - Clinical Overview, Pricing & Dosage Insight5.1 Overview5.2 Clinical Overview, Pricing & Dosage Insight 6. Approved Multispecific Antibodies - Sales Insight (2020 - Q1'2025) 7. Global Multispecific Antibodies Clinical Trials Overview 8. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase8.1 Research8.2 Preclinical8.3 Phase-I8.4 Phase-I/II8.5 Phase-II8.6 Phase-II/III8.7 Phase-III8.8 Preregistration8.9 Registered 9. Marketed Bispecific Antibodies Clinical Insight By Company, Country & Indication 10. Global Trispecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase10.1 Research10.2 Preclinical10.3 Phase I10.4 Phase I/II10.5 Phase II/III 11. Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase11.1 Preclinical11.2 Phase I11.3 Phase I/II11.4 Phase II 12. Competitive Landscape AbbVie ABL Bio Abzyme Therapeutics Affimed Therapeutics Akeso Biopharma Alligator Bioscience Amgen Antibody Therapeutics APITBIO Astellas Pharma AstraZeneca Aptevo Therapeutics BioAtla Biocytogen Pharmaceuticals Biosion EpimAb Biotherapeutics FutureGen Biopharmaceutical Genentech Genmab Genor Biopharma Gensun Biopharma Harbour BioMed IGM Biosciences I-MAB Biopharma ImmuneOnco Biopharma ImmunoPrecise Antibodies Innate Pharma Innovent Biologics Invenra Johnson & Johnson Kenjockety Biotechnology LaNova Medicines Limited Light Chain Bioscience Linton Pharm Lyvgen Biopharma MacroGenics Merck Merus ModeX Therapeutics (OPKO Health) Molecular Partners NovaRock Biotherapeutics Numab OPKO Health Pfizer Regeneron Pharmaceuticals Revitope Roche Sanofi Sichuan Baili Pharmaceutical SystImmune Virtuoso Therapeutics Xencor Y-Biologics Zhejiang Shimai Pharmaceutical Zymeworks For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 hours ago
- Yahoo
Novo Nordisk ramps up obesity fight, advances amycretin to Phase III
Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and who are overweight. Following a positive end-of-Phase II meeting, Novo Nordisk shared that regulatory authorities have approved the therapy to proceed. The company plans to initiate the trial in adults who are overweight or with obesity in Q1 2026. Executive vice president for development at Novo Nordisk, Martin Lange said: 'We are very pleased that the feedback from regulatory authorities has allowed us to take subcutaneous and oral amycretin in weight management to Phase III. We are excited about the amycretin molecule, and this marks an important step forward. We look forward to sharing more information on the design of the Phase III programme.' In a Phase Ib/IIa study (NCT06064006), amycretin, a glucagon-like peptide-1 (GLP-1) and amylin receptor co-agonist, showed weight-loss outcomes of up to 22% in 36 weeks. This was higher than seen by the company's blockbuster therapy Wegovy (semaglutide), which demonstrated a body weight change of 14% at week 36 in a Phase II study. The Phase Ia/IIb study investigated three doses of once-weekly subcutaneous amycretin in 125 patients who are overweight or with obesity. The primary endpoint was treatment-emergent adverse events (TEAEs), with Novo Nordisk reporting that the most common events were gastrointestinal, and the majority were mild to moderate in severity. If successful in a Phase III trial, GlobalData anticipates that amycretin will receive approval for adults with overweight or obesity in Q4 2030 in the US, followed by approval in the EU in Q1 2031. GlobalData is the parent company of Clinical Trials Arena. Novo Nordisk has signed a $812m partnership with Deep Apple Therapeutics to access novel compounds, not GLP-1RAs, for obesity and other diseases. As well as this, the company has also listed two new studies for CagriSema, another candidate in its pipeline. The company recently announced underwhelming data from a Phase III trial, which, while meeting its primary endpoint, fell short of the 25% weight loss promise. Following all these updates, Novo Nordisk's share price has now increased, making it the most valuable company in Europe once again. It has a market cap of $359.28bn compared to German software company SAP at $359bn. Novo Nordisk's flagship semaglutide, marketed as Wegovy in weight loss and Ozempic in type 2 diabetes, is forecast to make $49bn in sales in 2030, according to GlobalData. Its main competitor, Eli Lilly's tirzepatide, marketed as Zepbound in weight loss and Mounjaro in type 2 diabetes, is projected to reach sales of $60.8bn. Lilly's drug proved to have higher efficacy than Novo Nordisk's in a head-to-head study between the pair. "Novo Nordisk ramps up obesity fight, advances amycretin to Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
